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Abstract
Background: Frailty is common in clinical practice, but trials rarely report on participant frailty. Consequently,
clinicians and guideline-developers assume frailty is largely absent from trials and have questioned the relevance of
trial findings to frail people. Therefore, we examined frailty in phase 3/4 industry-sponsored clinical trials of
pharmacological interventions for three exemplar conditions: type 2 diabetes mellitus (T2DM), rheumatoid arthritis
(RA), and chronic obstructive pulmonary disease (COPD).
Methods: We constructed a 40-item frailty index (FI) in 19 clinical trials (7 T2DM, 8 RA, 4 COPD, mean age 42–65
years) using individual-level participant data. Participants with a FI > 0.24 were considered ‘frail’. Baseline disease
severity was assessed using HbA1c for T2DM, Disease Activity Score-28 (DAS28) for RA, and % predicted FEV1 for
COPD. Using generalised gamma regression, we modelled FI on age, sex, and disease severity. In negative binomial
regression, we modelled serious adverse event rates on FI and combined results for each index condition in a
random-effects meta-analysis.
Results: All trials included frail participants: prevalence 7–21% in T2DM trials, 33–73% in RA trials, and 15–22% in
COPD trials. The 99th centile of the FI ranged between 0.35 and 0.45. Female sex was associated with higher FI in
all trials. Increased disease severity was associated with higher FI in RA and COPD, but not T2DM. Frailty was
associated with age in T2DM and RA trials, but not in COPD. Across all trials, and after adjusting for age, sex, and
disease severity, higher FI predicted increased risk of serious adverse events; the pooled incidence rate ratios (per
0.1-point increase in FI scale) were 1.46 (95% CI 1.21–1.75), 1.45 (1.13–1.87), and 1.99 (1.43–2.76) for T2DM, RA, and
COPD, respectively.
Conclusion: The upper limit of frailty in trials is lower than has been described in the general population. However,
mild to moderate frailty was common, suggesting trial data may be harnessed to inform disease management in
people living with frailty. Participants with higher FI experienced more serious adverse events, suggesting screening
for frailty in trial participants would enable identification of those that merit closer monitoring. Frailty is identifiable
and prevalent among middle-aged and older participants in phase 3/4 drug trials and has clinically important safety
implications.
Keywords: Frailty, Randomised controlled trials, Diabetes mellitus, Rheumatoid arthritis, Chronic obstructive
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Background
As average life expectancy rises and multimorbidity in-
creases [1], frailty is becoming an increasingly important
consideration in the management of chronic disease [2].
Frailty describes a clinical state of decreased function
across multiple physiological systems characterised by
vulnerability to adverse health outcomes and decompen-
sation in response to physiological stress [2]. A large
number of measures exist to identify and quantify frailty;
however, two models have dominated the literature: the
frailty index and the frailty phenotype [2, 3]. The frailty
index (FI) is based on a ‘cumulative deficit’ model
wherein deficits including long-term conditions, symp-
toms, functional impairments, and laboratory abnormal-
ities are counted [4]. Larger deficit counts indicate a
greater degree of frailty. The main alternative to the FI,
the frailty phenotype, identifies frailty where three of the
following five specific criteria are met, unintentional
weight loss, weakness, slow gait speed, exhaustion, and
low physical activity [5]. Although distinct concepts,
there is considerable overlap in the populations identi-
fied by the frailty index and frailty phenotype [6]. Both
approaches have been widely validated and associated
with adverse health outcomes including mortality, hospi-
talisation and disability [2].
Managing chronic illness in people living with frailty is
challenging [2, 7], not least because randomised con-
trolled trials, which (via clinical guidelines) underpin safe
and effective management, are said to exclude people
with frailty [7–9]. As such, the applicability of trial find-
ings to people living with frailty is not clear. This leaves
clinicians uncertain about treatment effectiveness, which
further complicates management of patients whose care
is already complex and challenging.
Despite these concerns, direct evidence concerning
frailty in clinical trials is scarce. Very few trials have
measured frailty. Considering drug trials specifically, we
found three (the HYVET and SPRINT studies of hyper-
tension [10, 11] and TOPCAT study of heart failure
[12]) which performed post hoc analysis of frailty using
the frailty index and a fourth (TRILOGY ACS for un-
stable angina), which assessed frailty using the frailty
phenotype model in a subset of participants aged over
65 years [13]. Frailty was found to be prevalent in these
trials, but as all four specifically targeted older people, it
is not known whether frailty may also be found in the
much larger and more influential body of trials not spe-
cifically targeted at older people. More recently, a pooled
analysis of 14 cardiovascular trials in older people (153,
696 participants, mean age 70.8 years) showed that a
frailty index was associated with all-cause and cardiovas-
cular mortality, as well as cardiovascular events [14].
Hitherto, inferences about trial representativeness have
largely been based on the observation that, on applying
trial eligibility criteria to routine electronic health re-
cords, ineligible patients are older and frailer and have
more comorbidities [15]. Recently, however, on directly
measuring comorbidities using individual-level partici-
pant data (IPD) in 116 industry-funded trials, we found
that multimorbidity was common in trial participants
[16]. Although frailty is associated with multimorbidity,
it is a distinct entity [1] and it is not clear whether frailty
is also common among trial participants. Moreover,
since trial IPD contains rich data on physiological status
(e.g. albumin, haemoglobin, body mass index), symptoms
(e.g. breathlessness, fatigue), and function (e.g. impaired
mobility), there is the potential to measure frailty.
In this study, we use IPD from existing clinical trials
for three exemplar chronic conditions (type 2 diabetes
mellitus (T2DM), rheumatoid arthritis (RA), and chronic
obstructive pulmonary disease (COPD)) to construct a
frailty index. We then quantify the prevalence of frailty
in these clinical trial populations and examine whether
frailty is associated with serious adverse events in the
clinical trials studied.
Methods
Study design and participants
IPD from industry-sponsored clinical trials were identi-
fied from two repositories: Clinical Study Data Request
(CSDR) and the Yale University Open Data Access
(YODA) project. Trials were selected according to a pre-
specified protocol (Prospero CRD42018048202) as part
of a wider project assessing multimorbidity in clinical
trials. Trials were eligible for inclusion if they evaluated
pharmacological treatments for a long-term condition;
were registered with clinicaltrials.gov; started after 1
January 1990; were phase 2/3, 3, or 4; included ≥ 300
participants; and had an upper age limit ≥ 60 years (or
no maximum). From this wider set of trials, we selected
three exemplar conditions (T2DM, RA, and COPD) in
which to assess frailty. These conditions were chosen as
frailty is common, and has been shown to affect younger
people, in the context of these chronic conditions [1,
17–19]. Furthermore, frailty is a clinically relevant con-
cept in the management of these conditions, having been
highlighted as an important factor influencing treatment
targets [20, 21].
Procedures
We measured frailty using a frailty index approach,
based on the cumulative deficit model of frailty de-
scribed by Rockwood and Mitnitski [22]. A frailty index
is a count of health-related deficits (including long-term
health conditions, laboratory abnormalities, symptoms,
and functional limitations) across a range of physio-
logical and mental health domains. Each individual’s
frailty index value is calculated as the sum of deficits
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present, divided by the total number of deficits in the
frailty index. For example, an individual with 8 out of a
possible 40 deficits would have a frailty index of 0.2 (8/
40). The frailty index was used to measure frailty in the
HYVET, SPRINT and TOPCAT trials, is applicable at any
age [10–12, 23–25], and can be calculated from any data-
set where a sufficient number of deficits is recorded. It is
therefore suitable for measuring frailty in our set of trials.
A standard procedure exists for selecting variables for
inclusion as ‘deficits’ in a frailty index [26]. Deficits should
(i) be associated with age and poorer health, (ii) cover a
range of physiological areas (e.g. physiological measures,
physical function, long-term conditions from different
organ systems), and (iii) be neither ubiquitous in the target
population nor be very rare (e.g. < 1% prevalence in the
target population). We applied these criteria to possible
deficits identified from trial baseline data. Existing litera-
ture was used to judge if a deficit met the above criteria.
Symptoms and functional measures were identified
using baseline quality of life and symptom question-
naires. We used the same deficits for all trials within
each index condition. Deficits differed between index
conditions as different questionnaires were used in the
respective trials. Laboratory and anthropometric deficits
(e.g. blood pressure, body mass index) were identified
from baseline values. We excluded from the frailty index
any deficit with > 5% missing data. To assess if any vari-
ables were strongly correlated, we analysed all pairs of
deficits using the Pearson and Spearman’s rank correl-
ation coefficients (for pairs of binary and categorical
deficits, respectively). Where there was high correlation
(> 0.3), only one of the correlated variables was included
in the frailty index [27]. For each index condition, we
identified 40 deficits to be included in the frailty index
(supplementary appendix). Participants with complete
data for at least 38 of these deficits were included in the
analysis. The frailty index was calculated as the total
number of deficits present divided by the total number
of deficits with complete data for that individual.
We had intended to use medical history data to identify
long-term conditions, but this was frequently redacted (as
a privacy measure) or not recorded. We therefore identi-
fied long-term conditions based on concomitant medica-
tions, using definitions we have previously published [16].
Outcomes
Applying cut-off values to define frailty has proved con-
troversial, with no consensus on a value above which a
person should be identified as living with frailty. We
therefore report the entire distribution of the frailty
index for each trial. We also separately described the
distribution in trial participants above 65 years. To facili-
tate comparison with the published literature, we also
categorised the frailty index into no frailty (< 0.12), mild
(0.12–0.24), moderate (0.24–0.36), and severe frailty
(> 0.36), based on cut-points used in the electronic
frailty index (used in routine clinical practice) [27].
We assessed the relationship between frailty index and
the following baseline characteristics: age, sex, severity of
the index condition, and long-term condition count. We
assessed severity of T2DM by measuring glycated
haemoglobin (HbA1c) as a proxy marker, while in RA
we used the Disease Activity Score in 28 joints (DAS28)
and for COPD the forced expiratory volume in 1 s as a
percentage of predicted value (% predicted FEV1).
Finally, we assessed whether the frailty index at baseline
predicts serious adverse events during trial follow-up. Tri-
als record all adverse events occurring during the trial
period regardless of their relationship (or lack of relation-
ship) with the trial treatment. Certain adverse events are
characterised as ‘serious adverse events’ (SAEs). SAEs are
those meeting one or more of the following criteria: (i) re-
sults in death, (ii) is life threatening, (iii) results in hospi-
talisation, (iv) results in persistent or significant disability/
incapacity, or (v) is a congenital abnormality/birth defect.
Statistical analysis
All analyses were conducted according to a pre-specified
protocol.
All trial data were held within secure repositories that only
permit export of aggregate, non-identifiable data. Therefore,
to allow full description of the distribution of the frailty index
for each trial while avoiding the risk of disclosure, we used
statistical distributions to represent the frailty index. For each
trial, we fitted the frailty index to each of the following distri-
butions: lognormal, gamma, Weibull, and generalised
gamma. We then compared the fit of each distribution using
Kolmogorov-Smirnov tests (p > 0.05 taken as good fit, failing
to reject the null hypothesis that the distributions were dif-
ferent). The generalised gamma distribution was found to fit
the frailty index distribution well for all trials. Parameters de-
scribing the distribution for each trial were exported from
the secure environments to allow us to report the distribu-
tion of the frailty index for each trial. We calculated the
frailty distribution for the whole trial population. We then
repeated the process restricting the trial population to people
over 65 years.
We then modelled frailty index on age, sex, and dis-
ease severity using generalised gamma regression
models. Each trial was modelled separately. Non-linear
relationships between age, disease severity, and frailty
index were explored using fractional polynomials. There
was no improvement in model fit incorporating non-
linear terms. The coefficients and variance-covariance
matrices from these models were exported from the se-
cure environments to allow us to report the mean frailty
index for specific age, sex, and disease severity
combinations.
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Within the secure environments, we fitted negative bino-
mial models of serious adverse event rates on frailty index,
age, sex, and disease severity, exporting the coefficients and
variance covariance matrices as before. For each index con-
dition, we performed random-effects meta-analysis (using
inverse variance weighting) to obtain overall estimates of
the associations between serious adverse events and frailty
index (adjusted for age, sex, and disease severity).
Data processing and analysis was performed using R
(version 3.6.1). Meta-analyses were performed using




We identified 39 trials meeting our inclusion criteria for
which IPD were available in the CSDR or YODA reposi-
tories. Of these, 19 trials (7 T2DM trials, 8 RA trials, and
4 COPD trials) contained IPD on a range of variables suf-
ficient to calculate the frailty index. In the remaining 20
trials, data on functional deficits and/or laboratory mea-
sures were either redacted or not reported. The selection
of trials is summarised in Fig. 1. The characteristics of the
included trials are summarised in Table 1.
Distribution of frailty
The distribution of the frailty index for each trial is
shown in Fig. 2. Each trial included participants with
a wide range of frailty index values, and all trials in-
cluded some frail participants. Distributions were
similar within each index condition but differed sub-
stantially between the three conditions. Summary sta-
tistics for frailty in each trial, along with proportions
in each category of frailty, are shown in Table 2. Tak-
ing an illustrative cut-off of 0.24 to indicate frailty,
the proportion of trial participants with frailty ranged
from 7 to 21% in T2DM trials, 33 to 73% in RA tri-
als, and 15 to 22% in COPD trials.
Relationship with baseline factors
Estimated mean frailty index by age, sex, and disease se-
verity is shown in Fig. 3. Disease severity at baseline was
associated with frailty index for COPD and, especially,
for RA trials, but not for T2DM trials. Frailty was associ-
ated with female sex in all trials for all conditions. In the
COPD trials, the mean frailty index was not associated
with age, but for all of the RA trials and all but one
T2DM trials, the mean frailty index increased with age.
The variation by age was smaller than the variation be-
tween trials, however, and for all conditions, frailty
Fig. 1 Flow diagram of identification of trial individual participant data and inclusion in analysis
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remained common even among the youngest partici-
pants. For example, the modelled proportion of 40-year-
olds with a frailty index > 0.24 ranged from 4 to 15%, 6
to 52%, and 20 to 27% in T2DM, RA, and COPD,
respectively.
Frailty index and serious adverse events
The relationship between frailty index and the incidence
of serious adverse events occurring during trial follow-
up is summarised in Fig. 4. When the trials within each
condition were meta-analysed, a 0.1-point increment in
Fig. 2 Distribution of frailty index in each trial. a Type 2 diabetes trials. b Rheumatoid arthritis trials. c COPD trials
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frailty index at baseline was associated with a higher ser-
ious adverse event rate for all conditions (IRR 1.46 (95%
CI 1.21–1.75) for T2DM, 1.45 (1.13–1.87) for RA, and
1.99 (1.43–2.76) for COPD). Heterogeneity between tri-
als was high for RA, but low for T2DM and COPD. The
full model outputs for each trial are shown in the
Supplementary appendix. Therefore, for each condition,
after adjusting for age, sex, and disease severity, frailty




Using individual-level participant data for 19 trials for
three common and important chronic conditions—all
with a mean age of less than 65 years—we found that
frailty was highly prevalent among trial participants. The
frailty index showed the expected relationships with sex,
age (apart from in COPD), and disease severity and
identified trial participants at higher risk of serious ad-
verse events.
In context of existing literature
Few studies have attempted to measure frailty across
multiple clinical trials. To our knowledge, this is the first
to include trials not specifically targeting older popula-
tions (with most participants aged < 65 years) and the
first to do so for T2DM, RA, or COPD. Our findings
that frailty can be identified in trials are consistent with
two large hypertension trials, HYVET and SPRINT [10,
11], which focused on hypertension management in
older people, and one heart failure trial in older people
[12], which showed that frailty was relatively common in
these trials. We extend these findings by showing that
frailty is relatively common in ‘standard’ industry-funded
phase 3 trials in younger populations, that it is associ-
ated with baseline characteristics, and that frailty at
baseline predicts the risk of serious adverse events, even
after adjusting for age, sex, and the severity of the index
condition.
The frailty index in our analysis showed similar prop-
erties to observational studies of frailty using the frailty
index approach [22, 23, 26]. As expected, the frailty
Table 2 Mean frailty index, 99th centile, and proportion of participants in frailty categories for each trial: whole trial population and
those over 65 years













Frailty index categories (%)
0–0.12 0.12–0.24 0.24–0.36 > 0.36 0–0.12 0.12–0.24 0.24–0.36 > 0.36
Type 2 diabetes
NCT01106625 0.16 0.35 31.36 56.12 11.82 0.7 0.17 0.51 24.38 63.68 8.81 3.13 74 (16%)
NCT01106677 0.16 0.35 28.26 59.79 11.21 0.74 0.17 0.33 20.13 70.29 9.08 0.5 124 (10%)
NCT00734474 0.13 0.35 54.22 39.24 5.72 0.82 0.14 0.32 43.78 49.08 6.81 0.33 66 (5%)
NCT01064687 0.17 0.45 26.9 56.56 13.44 3.1 0.19 0.46 20.49 57.86 17.54 4.1 4 (0.4%)
NCT01075282 0.16 0.42 33.35 53.02 11.29 2.34 0.18 0.42 23.2 57.15 16.72 2.93 4 (0.5%)
NCT01191268 0.18 0.43 20.73 58.29 17.82 3.16 0.2 0.42 14.96 60.54 21.21 3.29 2 (0.2%)
NCT01624259 0.16 0.45 35.34 51.53 10.36 2.77 0.18 0.43 24.7 55.16 16.94 3.2 1 (0.2%)
RA
NCT00236028 0.26 0.41 2.62 37.05 53.73 6.6 0.27 0.41 1.15 28.08 61.5 9.27 12 (2%)
NCT00264537 0.28 0.44 1.14 25.99 58.83 14.05 0.31 0.46 0.16 15.63 63.43 20.78 4 (0.6%)
NCT00264550 0.27 0.45 2.03 34.71 51.37 11.89 0.28 0.41 3.58 24.91 57.11 14.41 2 (0.5%)
NCT00361335 0.28 0.45 1.49 29.24 55.43 13.85 0.29 0.46 0.73 26.31 56.99 15.96 1 (0.2%)
NCT00106535 0.22 0.4 11.57 46.97 37.19 4.27 0.24 0.4 9.73 39.92 44.71 5.64 4 (0.3%)
NCT01007435 0.2 0.4 18.92 47.79 29.95 3.35 0.21 0.41 15.89 46.55 32.81 4.75 9 (3%)
NCT01119859 0.24 0.44 8.5 43.27 39.88 8.36 0.25 0.48 7.07 40.41 40.3 12.22 3 (0.3%)
NCT01232569 0.22 0.4 10.32 49.31 36.44 3.93 0.23 0.4 7.59 47.37 41.24 3.8 0 (0%)
COPD
NCT01316900 0.18 0.35 24.62 55.68 18.9 0.8 0.17 0.35 25.83 57.28 16.3 0.58 33 (4%)
NCT01316913 0.18 0.35 22.04 55.71 21.56 0.69 0.18 0.35 24.64 55.33 19.38 0.65 19 (2%)
NCT01957163 0.17 0.37 27.13 55.71 15.74 1.42 0.17 0.36 28.32 56.89 13.79 1 0 (0%)
NCT02119286 0.16 0.35 30.74 53.91 14.67 0.68 0.16 0.33 30.75 56.81 12.1 0.34 2 (0.3%)
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index had a skewed distribution, was higher in women
than men, and for RA and T2DM was associated with
age. We have previously shown, using UK Biobank data,
that frailty is identifiable in younger as well as older
people [1], and the current work shows that this is also
true of trials.
While many of the characteristics of the frailty index
in the trial data are consistent with studies of frailty
using observational cohorts and administrative data [28],
the maximum frailty index in the trials (based on the
99th centile of the frailty index distribution) was lower
than is typically seen in observational studies [29]. Since
Fig. 3 Relationship between age, sex, disease severity and frailty index. a Type 2 diabetes trials. b Rheumatoid arthritis trials. c COPD trials
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this difference was also evident among trial participants
aged over 65, it cannot solely be attributed to the youn-
ger age of the trial participants. The extent to which this
difference is due to trial eligibility criteria [15, 30] (e.g.
comorbidities, renal function) or other selection pres-
sures on trial participation (such as the need to be able
to undergo multiple trial visits or procedures) is un-
known. This suggests that our findings hold for the
range of frailty index values we observed in these trials,
which is narrower than that observed in unselected
populations.
Importantly, while the very frailest patients were rarely
included in the clinical trials, we found moderate to se-
verely frail patients—who make up the bulk of those
with frailty in the community—were commonly included
as participants in clinical trials, despite those trials in-
volving younger people aged under 65 years. Many trials
require high disease activity/severity as inclusion criteria,
which is one potential explanation for the high preva-
lence of frailty in some trials, particularly in conditions
like RA where there is overlap between functional limi-
tations resulting from active disease and deficits in-
cluded in the frailty index.
It is notable that the frailty index in the COPD trials was
not associated with increasing age, as would be expected.
A similar phenomenon was also observed in both the
SPRINT and TOPCAT trials (of hypertension and heart
failure, respectively), whereby younger trial participants
showed relatively higher frailty index values compared to
relatively older trial participants [11, 12]. These COPD tri-
als (as well as previous trials showing similar associations)
may suggest that to be included in the trial, older people
with COPD tended to be relatively less frail than similarly
aged people with COPD in the general population. This
Fig. 4 Random-effects meta-analysis of incidence rate ratio of serious adverse events per 0.1 point increase in frailty index. (a) Type 2 diabetes
trials. (b) Rheumatoid arthritis trials. (c) COPD trials
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could arise due to the trial selection process [31], as an ex-
ample of collider bias, whereby conditioning on a subse-
quent outcome (trial inclusion) influences the relationship
between causally proximal characteristics such as age and
frailty [32]. We conducted exploratory analyses of the as-
sociation between age and the St George Respiratory
Questionnaire score and EQ 5D as these are known to in-
crease with age in unselected populations [33, 34]. Like
the frailty index, these were not associated with age in the
COPD trials. Furthermore, the mean frailty index is lower
in the COPD trials, and the range of frailty index values is
narrower, compared to the frailty index distribution in
previous observational studies of frailty in COPD [35].
This supports our speculation that the unexpected rela-
tionship between age and frailty index in these trials re-
flects differences between the trial population and people
in the community with the same condition.
Frailty index was moderately associated with disease
severity in COPD and RA. It would have been surprising
had there been no association, as functional limitation
and frailty, acting across multiple organ systems, are a
well-recognised consequence of both diseases [19, 21].
Moreover, FEV1 has long been established as a marker
of general physiological reserve as well as of lung dis-
ease. The fact that the correlation was not stronger is
perhaps of greater interest as it suggests that factors
other than the severity of the index disease are import-
ant drivers of frailty. Moreover, frailty index predicted
adverse events independently of disease severity, indicat-
ing that the frailty index contains important clinical in-
formation about trial participants beyond that captured
by disease-severity measures alone, possibly related to
the increasing prevalence of multimorbidity.
Strengths and limitations
A strength of our study is that we used a standard well-
validated approach to measure frailty [26], across a large
number of trials and a range of conditions, allowing
comparison of findings between trials and between con-
ditions. Our analysis also has some important limita-
tions, however. The trials included were not a random
sample, but instead were selected from trials that spon-
sors have made available to third-party researchers for
secondary analyses. Not all sponsors share IPD, and
those that do share data do not make all trials available.
Of the trials we did access, not all trials had sufficient
data to identify deficits for inclusion in a frailty index.
The data used to compile the frailty index were not
collected for the purpose of identifying frailty, although
this is true for most studies using the frailty index.
Moreover, medical history data were redacted in most of
the included trials, so we were therefore reliant on con-
comitant medication data to define long-term condition
count-based deficits. Consequently, some conditions
could only be included as part of a broader group (e.g.
cardiovascular disease, obstructive airways disease) ra-
ther than as a specific condition, while other conditions
(those without specific drug treatments) could not be in-
cluded [16]. This restricts the number of conditions that
could be included in our frailty index, and may result in
an under-estimate of the number of conditions present
(e.g. in people with multiple cardiovascular conditions
which are counted as a single category, or with condi-
tions such as chronic kidney disease which could not be
identified using prescribed medications). Furthermore,
we used existing instruments, primarily designed to
characterise the index condition, to measure functional
deficits of frailty (e.g. reduced mobility and difficulty
with household tasks were identified using St George
Respiratory Questionnaire in the context of COPD, and
using the Health Assessment Questionnaire Disability
Index in RA). It may be that instruments designed spe-
cifically to measure frailty would have improved sensitiv-
ity or specificity. Despite these limitations, and especially
compared with most administrative data sources, trial
data benefits from a wide range of physiological, bio-
chemical, haematological, and functional measures.
Moreover, given the regulatory conditions under which
trials are conducted, these data were collected, recorded,
and processed according to exacting standards.
Implications
Current guidelines caution against the extrapolation of
trial evidence to frail people [7, 20], and clinicians lack
high-quality evidence about the benefits and harms of
common treatments for people living with frailty. Our
findings demonstrate that it is feasible to measure frailty,
using an established, validated method—the frailty
index—in standard industry-funded drug trials, and that
on doing so significant numbers of trial participants have
mild to moderate frailty. As such, while such trials can-
not be claimed to be representative of people with frailty,
particularly those with severe frailty who were very
rarely found to be present, trials nonetheless contain im-
portant under-used information to help address current
evidence gaps.
We were able to identify frailty in trials only because
we were able to access trial IPD, which is complex and
time-consuming. Moreover, several trials redacted data
(and, less often, did not collect sufficient data) to allow
us to calculate a frailty index. Both to allow clinicians to
assess the degree to which frailty is under-represented in
particular trials, and to understand whether and how
treatment effects differ by frailty (realistically only feas-
ible via meta-analysis of multiple trials), there is a need
to expand existing trial conduct and reporting standards
[36], to include standard measures of frailty. Our
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findings suggest that frailty is sufficiently common in tri-
als for this to be a worthwhile exercise.
To that end, standard approaches to the collection
and reporting of medical history data (to allow accur-
ate assessment of comorbidities to be included in a
frailty index) as well as measures specifically designed
to assess frailty (e.g. the frailty phenotype) should be
incorporated into international standards for the con-
duct of trials. Ideally, the adoption of complementary
measures such as the frailty index and frailty pheno-
type measures should be considered. The frailty index
can be applied to routinely collected trial data, but is
likely to be more influenced by multimorbidity (and
in turn, trial inclusion criteria) while the frailty
phenotype may identify trial participants with more
explicitly defined physiological frailty, some of whom
may not have multimorbidity. Given the well-
resourced and rigorous measurement and reporting
usual in well-conducted trials, the adoption of stand-
ard measures of frailty across trials is highly feasible
and would allow estimation of the impact of frailty
on treatment effects both for individual trials and for
meta-analyses of multiple trials. It would also enable
identification of participants with increased frailty
who are at increased risk of more serious adverse
events, who might benefit from closer monitoring.
Conclusion
Contrary to the prevailing view [7, 8], frailty, albeit
not the most severe frailty, is common and readily
measurable among clinical trial participants. This in-
cludes trials of relatively young populations. We have
shown that participants with increased frailty at base-
line also experience more serious adverse events, sug-
gesting that such patients might merit closer
monitoring and that screening for frailty should be
considered for addition to future Consort checklists.
Future research should evaluate whether frailty in tri-
als is associated with treatment effectiveness. Both
existing and future drug trials have the potential to
inform the management of individuals living with
frailty. Trialists therefore can and should routinely
measure and report frailty. However, to do so frailty
needs to become a standard measure within trials.
Ideally, this would include both standardised assess-
ment of comorbidities and baseline functional status
(from which a frailty index could be consistently con-
structed) as well as physiological measurements to as-
sess the frailty phenotype. There is also a need for
research specifically targeting people with severe
frailty, who were rarely included in these trials, and
for whom the risks and benefits of treatments are
most uncertain. Given ageing population demograph-
ics as well as the presence of frailty among relatively
younger people, such measures would be central to
understanding how treatments should be applied to
the growing numbers of people living with frailty.
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